SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Akebia Therapeutics logo
4 months ago

Director, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)Other$214K/yr – $289K/yr
Akebia Therapeutics logo
4 months ago

Product Manager, Marketing

Akebia Therapeutics

Cambridge, MA (Unknown)$110K/yr – $135K/yr
Akebia Therapeutics logo
4 months ago

Associate Director, Marketing

Akebia Therapeutics

Cambridge, MA (Unknown)$177K/yr – $219K/yr
Akebia Therapeutics logo
4 months ago

Product Manager, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)Other$110K/yr – $148K/yr
Akebia Therapeutics logo
4 months ago

Associate Director, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)Other$177K/yr – $240K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Akebia Therapeutics logo

Director, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)

$214K/yr - $289K/yrIn-houseOtherDirector/executive
4 months ago
Akebia Therapeutics logo

Product Manager, Marketing

Akebia Therapeutics

Cambridge, MA (Unknown)

$110K/yr - $135K/yrIn-houseMid level3+ years exp.
4 months ago
Akebia Therapeutics logo

Associate Director, Marketing

Akebia Therapeutics

Cambridge, MA (Unknown)

$177K/yr - $219K/yrIn-houseManager7+ years exp.
4 months ago
Akebia Therapeutics logo

Product Manager, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)

$110K/yr - $148K/yrIn-houseOtherMid level3+ years exp.
4 months ago
Akebia Therapeutics logo

Associate Director, Marketing

Akebia Therapeutics

Cambridge, MA (Hybrid)

$177K/yr - $240K/yrIn-houseOtherMid level7+ years exp.
4 months ago
Akebia Therapeutics logo
Akebia Therapeutics

Director, Marketing

Cambridge, MA (Hybrid)

$214K/yr – $289K/yrDirector/ExecutiveOther

Posted 4 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive Vafseo brand strategy and cross-functional leadership to deliver compliant promotions and measurable marketing impact in pharma.

  • Own brand strategy and campaign execution across integrated programs
  • Must-have: 10+ years in pharma branding and MBA preferred
  • Standout: AI-enabled initiatives and cross-functional leadership

Job Description

Responsibilities

  • Lead development of overall Vafseo brand strategy and message
  • Manage day-to-day brand operations, ensuring timely execution of campaigns and materials across integrated promotional programs (personal promotion, non-personal promotion, peer-to-peer programs and Key Medical Expert engagement)
  • Partner with Commercial Analytics to generate customer and performance insights and lead the translation of those insights and field feedback into clear strategic priorities and actionable marketing programs
  • Partner with key stakeholders across Medical Affairs, Market Access, Sales, Regulatory, Legal and Compliance to deliver high-quality, compliant promotional and educational content
  • Effectively lead agencies to achieve high quality deliverables within time and budget scopes
  • Champion strategic project initiatives to drive future brand growth and operational efficiencies, including AI-enabled solutions
  • Define KPIs to measure marketing performance, ROI, brand impact and contribution to prescription growth; regularly report outcomes and optimization recommendations to leadership.
  • Manage budget to corporate targets
  • Contribute to a collaborative, mission-driven culture focused on delivering meaningful outcomes for patients
  • Effectively build, lead, coach and manage teams supporting achievement of business objectives and employee development

Requirements

  • Bachelor's Degree required, MBA is a plus
  • Minimum of 10 years in the pharmaceutical or biotech industry and 8+ years of proven experience in brand marketing
  • People management experience

Nice To Have

  • Experience in nephrology is a plus
  • Experience in developing and executing personal, non-personal and peer-to-peer marketing
  • Proven ability to influence without authority and partner with cross-functional teams in the development and delivery of brand strategic imperatives
  • Proven project and vendor management skills including budget management, planning, prioritization, objective setting, and logistics execution
  • Strong written and presentation skills
  • Ability to travel up to 20% to attend sales meetings, customer visits and relevant medical congresses within the U.S.

Benefits

  • health care
  • vision
  • dental
  • retirement
  • PTO
Akebia Therapeutics logo

Akebia Therapeutics

3.4 Glassdoor

Akebia Therapeutics, Inc. is a growing biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the development and commercialization of therapeutics for people living with kidney disease. Please review our social media guidelines at: https://akebia.com/social-media-guidelines/

Founded in 2007
Cambridge, Massachusetts, USA
273 employees (10 in marketing)
www.akebia.com
62% recommend to a friend
90% CEO approval

Traffic Signals

Monthly Visitors
9.1K
Traffic Source Mix
Search
42.4%
Direct
43.2%
Referral
5.8%
Social
7.3%
Paid
1.1%

Headcount Trend

Current headcount: ~273

Marketing Team

Marketing Team Size
9 (3% of company)

Funding

Total Funding
$442.5M
Last Raise
$37M
Post IPO Debt, 2 years ago

Funding History

  • Jan 2024
    Post IPO Debt • $37M
  • May 2020
    Post IPO Equity • $151.8M
  • Nov 2019
    Post IPO Debt • $100M

Recent News

Is Akebia Therapeutics Inc. stock cheap at current valuation
Nov 19, 2025 • newser.com
Tools to assess Akebia Therapeutics Inc.’s risk profile - Trade Analysis Summary & Technical Confirmation Trade Alerts
Nov 18, 2025 • newser.com
Akebia Therapeutics amends license agreement with Medice for Vafseo supply
Nov 17, 2025 • investing.com
Akebia Therapeutics Amends License Agreement with MEDICE
Nov 17, 2025 • TipRanks
Why Akebia Therapeutics (AKBA) Is Up After Strong Q3 Earnings and Promising Vafseo Kidney Data
Nov 13, 2025 • simplywall.st
Implied Volatility Surging for Akebia Therapeutics Stock Options
Nov 13, 2025 • Yahoo Finance
Akebia Therapeutics (AKBA): Valuation Insights Following Q3 Profit Surge and Positive Vafseo Clinical Update
Nov 12, 2025 • Yahoo Finance
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Nov 11, 2025 • Yahoo Finance
A Look at Akebia Therapeutics (AKBA) Valuation Following Q3 Profit and New Vafseo Clinical Data
Nov 11, 2025 • simplywall.st
Akebia Therapeutics Inc (AKBA) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
Nov 10, 2025 • Yahoo Finance
Akebia Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025 • GlobeNewswire
Akebia (NASDAQ: AKBA) to present at Guggenheim and Jefferies in November
Nov 4, 2025 • Stock Titan
Revenues Working Against Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Share Price Following 25% Dive
Nov 4, 2025 • simplywall.st
Akebia Therapeutics to Present at Upcoming Investor Conferences
Nov 4, 2025 • Sahm
Q3 EPS Estimate for Akebia Therapeutics Increased by Analyst
Nov 3, 2025 • MarketBeat
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 3, 2025 • Yahoo Finance
Akebia Therapeutics (AKBA) Expected to Announce Earnings on Thursday
Oct 31, 2025 • MarketBeat
Akebia Therapeutics (Nasdaq: AKBA) schedules Nov. 10, 8 a.m. EST results call
Oct 30, 2025 • Stock Titan
Akebia Therapeutics (AKBA) Receives Revised Price Target from HC Wainwright & Co. | AKBA Stock News
Oct 30, 2025 • GuruFocus
Akebia Therapeutics (NASDAQ:AKBA) Shares Gap Down - Here's Why
Oct 30, 2025 • MarketBeat
Akebia Therapeutics (AKBA) Is Down 29.9% After Ending VALOR Trial for Non-Dialysis CKD Patients
Oct 30, 2025 • Yahoo Finance
Akebia Therapeutics Stock Slumps After FDA Meeting Ends Without Path Forward for Vafseo Label Expansion
Oct 29, 2025 • Stocktwits
Akebia scraps plan for Vafseo trial after discussions with FDA
Oct 29, 2025 • Fierce Pharma
Akebia stock tumbles after FDA meeting on vadadustat trial design
Oct 29, 2025 • investing.com
FDA setback prompts Akebia to give up on broader Vafseo label
Oct 29, 2025 • The Pharma Letter
Akebia stock plunges as kidney drug expansion plans scrapped
Oct 29, 2025 • The Business Journals
Akebia Therapeutics: Dialysis-Only Path Puts VOCAL/Protocol Wins At The Core (NASDAQ:AKBA)
Oct 29, 2025 • Seeking Alpha
Akebia Abandons Non-Dialysis Trial For Vafseo On Likely Higher Costs
Oct 29, 2025 • Citeline News & Insights
Akebia (NASDAQ: AKBA) to forgo broad Vafseo label in NDD‑CKD post FDA Type C meeting
Oct 28, 2025 • Stock Titan
Akebia Therapeutics Halts VALOR Trial for Vadadustat
Oct 28, 2025 • TipRanks
Akebia Therapeutics Provides Update on Vafseo for Non-Dialysis Patients
Oct 28, 2025 • Yahoo Finance
Akebia ditches plans for Vafseo label expansion
Oct 28, 2025 • FirstWord Pharma
Akebia Therapeutics (AKBA) Halts Expansion Plans for Vafseo
Oct 28, 2025 • GuruFocus
Akebia plummets as it abandons Vafseo for non-dialysis patients
Oct 28, 2025 • Seeking Alpha
Akebia Therapeutics’ Pediatric Anemia Study Withdrawn: Market Implications
Oct 27, 2025 • TipRanks
Comparing Akebia Therapeutics Inc. in custom built stock radars - July 2025 Pullbacks & Weekly High Potential Stock Alerts
Oct 24, 2025 • newser.com
Can Akebia Therapeutics Inc. (AX9) stock deliver strong annual returns - Weekly Profit Report & Community Trade Idea Sharing
Oct 24, 2025 • newser.com
Is Akebia Therapeutics Inc. (AX9) stock undervalued at current price - Earnings Beat & Weekly High Conviction Trade Ideas
Oct 24, 2025 • newser.com
How rising interest rates impact Akebia Therapeutics Inc. stock - Bull Run & Free Safe Entry Trade Signal Reports
Oct 24, 2025 • newser.com
Is Akebia Therapeutics Inc. (AX9) stock attractive for growth funds - Stock Surge & Weekly High Return Stock Opportunities
Oct 23, 2025 • newser.com
How forex fluctuations impact Akebia Therapeutics Inc. (AX9) stock - Risk Management & Daily Growth Stock Tips
Oct 22, 2025 • newser.com
Can Akebia Therapeutics Inc. (AX9) stock deliver strong annual returns - Portfolio Value Summary & Low Risk High Reward Trade Ideas
Oct 21, 2025 • newser.com
Is this a good reentry point in Akebia Therapeutics Inc. - Trend Reversal & AI Enhanced Execution Alerts
Oct 20, 2025 • newser.com
What makes Akebia Therapeutics Inc. stock attractive to growth funds - July 2025 Update & Free Long-Term Investment Growth Plans
Oct 20, 2025 • newser.com
Akebia Therapeutics to Present New Data on Vafseo® at ASN Kidney Week 2025
Oct 20, 2025 • Quiver Quantitative
Akebia Therapeutics Announces Five Presentations at ASN Kidney Week 2025
Oct 20, 2025 • GlobeNewswire
Five Presentations: Akebia Showcases Vafseo Real-World, Dosing & Win-Odds Data at ASN Kidney Week
Oct 20, 2025 • Stock Titan
How Akebia Therapeutics Inc. stock performs in interest rate cycles - 2025 AllTime Highs & Intraday High Probability Alerts
Oct 18, 2025 • newser.com
Will Akebia Therapeutics Inc. stock see insider buying - 2025 Key Highlights & High Conviction Trade Alerts
Oct 18, 2025 • nchmf.gov.vn
Support Test: Is Akebia Therapeutics Inc. stock dividend yield sustainable - July 2025 Outlook & Precise Swing Trade Entry Alerts
Oct 18, 2025 • nchmf.gov.vn
How Akebia Therapeutics Inc. stock reacts to inflationary pressures - July 2025 Rallies & Free Accurate Trade Setup Notifications
Oct 18, 2025 • nchmf.gov.vn
Will Akebia Therapeutics Inc. stock see insider buying - Market Sentiment Summary & Consistent Profit Trading Strategies
Oct 18, 2025 • nchmf.gov.vn
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook
Oct 7, 2025 • simplywall.st
Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) Profit Outlook
Oct 7, 2025 • Sahm
204,163 Stock Options: Akebia Therapeutics Awards New Employee Grants with 4-Year Vesting Terms
Oct 1, 2025 • Stock Titan
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 1, 2025 • GlobeNewswire
Retail investors who have a significant stake must be disappointed along with institutions after Akebia Therapeutics, Inc.'s (NASDAQ:AKBA) market cap dropped by US$50m
Sep 11, 2025 • simplywall.st
Akebia at H.C. Wainwright: Strategic Growth in Anemia Treatment
Sep 8, 2025 • Investing.com
Akebia Therapeutics, Inc. (NASDAQ:AKBA) most popular amongst individual investors who own 55% of the shares, institutions hold 43%
Sep 6, 2025 • Yahoo Finance
Transcript : Akebia Therapeutics, Inc. Presents at Wells Fargo 20th Annual Healthcare Conference 2025, Sep-04-2025 08
Sep 5, 2025 • MarketScreener
Akebia at Wells Fargo Conference: Strategic Growth in Healthcare
Sep 4, 2025 • Investing.com
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - September 2, 2025
Sep 3, 2025 • BioSpace
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025 • GlobeNewswire
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025 • Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 2, 2025 • Akebia Therapeutics, Inc.
Akebia Therapeutics: Post-Earnings Dip Looks Like A Discounted Entry Ahead Of A Vafseo Inflection
Aug 28, 2025 • Seeking Alpha
Kidney Disease Biotech Akebia Therapeutics Set for Key Presentations at Major September Conferences
Aug 28, 2025 • Stock Titan
Akebia Therapeutics to Present at Upcoming Investor Conferences
Aug 28, 2025 • Yahoo Finance
Akebia Therapeutics to Present at Upcoming Investor Conferences
Aug 28, 2025 • Akebia Therapeutics, Inc.
Dialysis Induced Anemia Treatment Market Poised for Strong Growth, Doubling to USD 4.5 Billion by 2035
Aug 26, 2025 • EIN Presswire
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 22, 2025 • BioSpace
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025 • Yahoo Finance
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025 • Akebia Therapeutics, Inc.
Akebia, IRC announce broad availability of Vafseo across IRC dialysis clinics
Aug 21, 2025 • thefly.com
Akebia Therapeutics and Innovative Renal Care Announce Nationwide Availability of Vafseo® (vadadustat) Across All IRC Dialysis Clinics
Aug 21, 2025 • Morningstar.com
Akebia Therapeutics (AKBA) Bounces to Profitability amid Kidney Treatment Growth
Aug 19, 2025 • Yahoo Finance
Akebia Therapeutics Reports Record Revenue and Strategic Growth
Aug 12, 2025 • TipRanks
The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts
Aug 10, 2025 • Yahoo Finance
Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment?
Aug 10, 2025 • simplywall.st
Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024)
Aug 9, 2025 • Yahoo Finance
Akebia Therapeutics Reports Strong Q2 2025 Growth
Aug 7, 2025 • TipRanks
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Aug 7, 2025 • Yahoo Finance
Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops
Aug 7, 2025 • Investing.com
Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62.
Aug 7, 2025 • GuruFocus
Akebia Therapeutics, Inc. SEC 10-Q Report
Aug 7, 2025 • TradingView
Akebia Therapeutics Q2 revenue smashes expectations
Aug 7, 2025 • MarketScreener
Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Aug 7, 2025 • Akebia Therapeutics, Inc.
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Aug 6, 2025 • Yahoo Finance
Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference
Aug 6, 2025 • Morningstar.com
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Aug 4, 2025 • GlobeNewswire
Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization
Aug 4, 2025 • Yahoo Finance
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - August 1, 2025
Aug 3, 2025 • BioSpace
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 1, 2025 • Akebia Therapeutics, Inc.
Akebia Therapeutics Earnings: Q2 2025 Financial Results Coming August 7 - Key Details for Investors
Jul 31, 2025 • Stock Titan
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Jul 31, 2025 • Yahoo Finance
Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights
Jul 31, 2025 • Akebia Therapeutics, Inc.
Akebia Therapeutics Stock Dips Amid Financial Challenges
Jul 25, 2025 • StocksToTrade
H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy
Jul 25, 2025 • Yahoo Finance
Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share
Jul 22, 2025 • Yahoo Finance
Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know
Jul 16, 2025 • Yahoo Finance